Literature DB >> 19721073

Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.

Duy An Duong1, Thi Hong Duyen Nguyen, Thi Ngoc Lan Nguyen, Viet Hoa Dai, Thi Minh Ha Dang, Sy Kiet Vo, Dang Anh Thu Do, Van Vinh Chau Nguyen, Huy Dung Nguyen, Ngoc Sy Dinh, Jeremy Farrar, Maxine Caws.   

Abstract

Consecutive fluoroquinolone (FQ)-resistant isolates (n = 109) identified at the Pham Ngoc Thach Hospital for Tuberculosis, Ho Chi Minh City, Vietnam, were sequenced in the quinolone resistance-determining regions of the gyrA and gyrB genes and typed by large sequence polymorphism typing and spoligotyping to identify the Beijing genotype of Mycobacterium tuberculosis. Beijing genotype prevalence was compared with 109 consecutive isolates from newly presenting patients with pulmonary tuberculosis from the hospital outpatient department. Overall, 82.6% (n = 90/109) of isolates had mutations in gyrAB. Nine novel mutations were identified in gyrB (S486F, N538T, T539P, D500A, D500H, D500N, G509A, E540V, and E540D). The influence of these novel gyrB mutations on FQ resistance is not proven. The Beijing genotype was significantly associated with FQ resistance (odds ratio [OR], 2.39 [95% confidence interval {CI}, 1.34 to 4.25]; P = 0.003). Furthermore, Beijing genotype FQ-resistant isolates were significantly more likely than FQ-resistant isolates of other genotypes to have gyrA mutations (OR, 7.75 [95% CI, 2.84 to 21.15]; P = 0.0001) and high-level (>8 microg/ml) FQ resistance (OR, 11.0 [95% CI, 2.6 to 47.0]; P = 0.001). The underlying mechanism of the association of the Beijing genotype with high-level FQ resistance in this setting remains to be determined. The association of the Beijing genotype with relatively high-level FQ resistance conferred by specific gyrA mutations reported here is of grave concern given the epidemic spread of the Beijing genotype and the current hopes for shorter first-line treatment regimens based on FQs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721073      PMCID: PMC2772334          DOI: 10.1128/AAC.00541-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Fluoroquinolones: a new treatment for tuberculosis?

Authors:  S H Gillespie; N Kennedy
Journal:  Int J Tuberc Lung Dis       Date:  1998-04       Impact factor: 2.373

2.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

3.  Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.

Authors:  Y S Yoon; H J Lee; H I Yoon; C-G Yoo; Y W Kim; S K Han; Y-S Shim; J-J Yim
Journal:  Int J Tuberc Lung Dis       Date:  2005-11       Impact factor: 2.373

4.  Establishment and development of the National Tuberculosis Control Programme in Vietnam.

Authors:  N T Huong; B D Duong; N V Co; H T Quy; L B Tung; M Bosman; A Gebhardt; J P Velema; J F Broekmans; M W Borgdorff
Journal:  Int J Tuberc Lung Dis       Date:  2005-02       Impact factor: 2.373

5.  High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002.

Authors:  P Dewan; A Sosnovskaja; V Thomsen; J Cicenaite; K Laserson; I Johansen; E Davidaviciene; C Wells
Journal:  Int J Tuberc Lung Dis       Date:  2005-02       Impact factor: 2.373

Review 6.  The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.

Authors:  T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2004-12       Impact factor: 2.373

7.  Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam.

Authors:  H T Quy; T N Buu; F G J Cobelens; N T N Lan; C S B Lambregts; M W Borgdorff
Journal:  Int J Tuberc Lung Dis       Date:  2006-02       Impact factor: 2.373

8.  Variable host-pathogen compatibility in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Kathryn DeRiemer; Tran Van; Midori Kato-Maeda; Bouke C de Jong; Sujatha Narayanan; Mark Nicol; Stefan Niemann; Kristin Kremer; M Cristina Gutierrez; Markus Hilty; Philip C Hopewell; Peter M Small
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA.

Authors:  Subray S Hegde; Matthew W Vetting; Steven L Roderick; Lesley A Mitchenall; Anthony Maxwell; Howard E Takiff; John S Blanchard
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

10.  Beijing/W genotype Mycobacterium tuberculosis and drug resistance.

Authors: 
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

View more
  44 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

2.  Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings.

Authors:  I Kontsevaya; S Mironova; V Nikolayevskyy; Y Balabanova; S Mitchell; F Drobniewski
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

3.  Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis.

Authors:  Jurriaan E M de Steenwinkel; Marian T ten Kate; Gerjo J de Knegt; Henri A Verbrugh; Rob E Aarnoutse; Martin J Boeree; Michael A den Bakker; Dick van Soolingen; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  Disclosure of selective advantages in the "modern" sublineage of the Mycobacterium tuberculosis Beijing genotype family by quantitative proteomics.

Authors:  Jeroen de Keijzer; Petra E de Haas; Arnoud H de Ru; Peter A van Veelen; Dick van Soolingen
Journal:  Mol Cell Proteomics       Date:  2014-07-14       Impact factor: 5.911

5.  Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis.

Authors:  Satoshi Mitarai; Seiya Kato; Hideo Ogata; Akio Aono; Kinuyo Chikamatsu; Kazue Mizuno; Emiko Toyota; Akiko Sejimo; Katsuhiro Suzuki; Shiomi Yoshida; Takefumi Saito; Ataru Moriya; Akira Fujita; Shuko Sato; Tomoshige Matsumoto; Hiromi Ano; Toshinori Suetake; Yuji Kondo; Teruo Kirikae; Toru Mori
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

6.  Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.

Authors:  Hyun Kim; Chie Nakajima; Kazumasa Yokoyama; Zeaur Rahim; Youn Uck Kim; Hiroki Oguri; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

7.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  Amino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae.

Authors:  Kazumasa Yokoyama; Hyun Kim; Tetsu Mukai; Masanori Matsuoka; Chie Nakajima; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

9.  Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.

Authors:  Shahul Hameed P; Anandkumar Raichurkar; Prashanti Madhavapeddi; Sreenivasaiah Menasinakai; Sreevalli Sharma; Parvinder Kaur; Radha Nandishaiah; Vijender Panduga; Jitendar Reddy; Vasan K Sambandamurthy; D Sriram
Journal:  ACS Med Chem Lett       Date:  2014-06-02       Impact factor: 4.345

10.  Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Authors:  Pooja Singh; Amita Jain; Pratima Dixit; Shantanu Prakash; Indu Jaiswal; Vimala Venkatesh; Mastan Singh
Journal:  J Antibiot (Tokyo)       Date:  2014-07-23       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.